Chrysalis Clinical welcomes Victoria Potarina to the Board as its new Director and Chief Growth Officer with effect from 1 May 2022 following her initial appointment as Partner, High Growth Ventures in January 2022.

Victoria, also known as Vika, brings a wealth of industry expertise combined with impressive strategy consulting skills and an entrepreneurial mindset. She has more than 12 years of international executive experience with Johnson & Johnson across multiple businesses and markets, was CEO of an ASX-listed Australian Medtech company and most recently acted as interim CEO of the Australian Clinical Trials Alliance.

Nick Northcott, the Managing Partner of Chrysalis, welcomed Vika onboard: “Vika brings to her new role a strong experience to lead the business growth of Chrysalis Clinical which will see her assist leading health research organisations in the areas of Clinical Research Governance, Clinical Research Integrity and Strategy Development. I extend Vika a warm welcome and I look forward to working with her in the many challenges and opportunities ahead in these areas”.

Vika is a Graduate Member of the Australian Institute of Company Directors and graduated with Masters (Hons) in Applied Linguistics from the Moscow State Linguistic University. Vika undertook a Senior Executive Program at London Business School and is currently an MBA candidate with the Macquarie Graduate School of Management.

Vika’s appointment follows Chrysalis Clinical’s growing opportunity and mission to assist health services and research organisations to transform their research capabilities to improve patient outcomes.